PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
 
Eur J Pharmacol. Author manuscript; available in PMC 2010 June 25.
Published in final edited form as:
PMCID: PMC2855957
EMSID: UKMS29044

New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells

Abstract

Ionising radiation plays a key role in therapy due to its ability to directly induce DNA damage, in particular DNA double-strand breaks leading to cell death. Cells have multiple repair pathways which attempt to maintain genomic stability. DNA repair proteins have become key targets for therapy, using small molecule inhibitors, in combination with radiation and or chemotherapeutic agents as a means of enhancing cell killing. Significant advances in our understanding of the response of cells to radiation exposures has come from the observation of non-targeted effects where cells respond via mechanisms other than those which are a direct consequence of energy-dependent DNA damage. Typical of these is bystander signalling where cells respond to the fact that their neighbours have been irradiated. Bystander cells show a DNA damage response which is distinct from directly irradiated cells. In bystander cells, ATM- and Rad3-related (ATR) protein kinase-dependent signalling in response to stalled replication forks is an early event in the DNA damage response. The ATM proteine kinase is activated downstream of ATR in bystander cells. This offers the potential for differential approaches for the modulation of bystander and direct effects with repair inhibitors which may impact on the response of tumours and on the protection of normal tissues during radiotherapy.

Keywords: DNA damage, radiotherapy, bystander effects, DNA repair

1. Introduction – Ionising radiation induced DNA damage and repair

The use of ionising radiation in radiotherapy is based around the principle of direct radiation exposure leading to critical DNA damage which ultimately results in tumour cell death. Over 50 years of research has mapped out the pathways which sense DNA damage within cells leading to downstream activation of repair processes. Ionising radiation is unlike many other genotoxic agents in that the yields and distributions of DNA damage are highly complex. For example, multiple types of lesions can be induced which include various types of base damage (up to 20 have been characterised), breaks in the helix either as single-(ssb) or double-strand breaks (dsb) and covalent bond formation leading to DNA-protein crosslinks and DNA-DNA crosslinks. The yields of these individual lesions also vary for a typical radiation dose of 1Gy from around 3000 base damages to around 30-40 dsb. Another significant factor is that this damage is not uniformly distributed throughout the genome after exposures. Radiation deposits its energy via “radiation tracks” where energy deposition events are localised to each other as these tracks cross a cell nucleus, leading to clustering of lesions on the DNA within 0-20 bp. The degree of clustering is determined by the ionisation density or the radiation quality with more densely ionising radiation such as neutrons and alpha-particles producing more clustered damage than sparsely ionising radiation such as X-rays and γ-rays. Of these lesions it is thought that DNA dsb are highly toxic to cells alongside some classes of clustered lesions, as they are more difficult to repair (Goodhead, 1994).

Cells have evolved a battery of repair pathways for maintaining genomic stability. For ionising radiation two main pathways exist to repair dsb, non-homologous end-joining and homologous recombination (see figure 1). Non-homologous end-joining is the main pathway by which cells repair ionising radiation damage as it does not require a template for repair and involves some limited processing of the damaged ends prior to re-ligation of the dsb. Key components involve the Ku heterodimer which binds to the dsb ends and enables recruitment of a range of proteins starting with DNA PKcs to form DNA-PK and others including Artemis with finally DNA ligase IV binding to seal the break. The non-homologous end-joining pathway is sometimes referred to as being error prone due to the lack of template. The alternative homologous recombination pathway is active during S and G2-phase as it allows an error free repair using a sister chromatid as a template. This involves an excision repair type process with strand invasion into the sister chromatid, involving multiple proteins including Rad51, BRCA2 and Rad54.

Figure 1
Depiction of the two main processes for repairing DNA dsb in mammalian cells. In NHEJ, the break is processed and rejoined with the possibility of sequence information being lost and incorrect repair. With HR an intact homolog is used as a template to ...

DNA dsb can be repaired by either HR or non-homologous end-joining, however it is also known that if damage accumulates at S-phase during replication that stalled replication forks can be produced leading to the indirect production of dsb (Lobrich and Jeggo, 2007).

The other key pathway used for repairing ionising radiation damage is the base excision repair pathway. This can repair damaged bases and also ssb using the undamaged strand of the DNA helix as a template.

2. Therapeutic application of small molecular inhibitors of DNA repair and cell cycle control proteins

DNA damage repair and cell cycle control proteins have recently attracted attention as molecular drug targets for the treatment of malignant tumours in combination with chemotherapy and radiotherapy. The overarching rationale is the induction of DNA damage by chemotherapeutic agents or ionising radiation in conjunction with the inhibition of DNA damage repair. Malignant tumours frequently consist of rapidly proliferating cells where the combination of DNA damage induction and interference with its adequate repair will subsequently result in increased cell death.

A number of small molecular inhibitors of proteins involved in DNA repair and cell cycle control are currently being developed including small molecular inhibitors of poly-adenosine diphosphate-ribose polymerase -1 (PARP-1), DNA -dependent protein kinase (DNA-PK), ataxia-telangiectasia mutated (ATM) protein kinase and Chk1.

The pre-clinical evaluation of PARP-1 inhibitors for therapeutic use, like AG14361, AG14447, AG014699, and CEP-6800 (Curtin et al., 2004; Miknyoczki et al., 2003; Thomas et al., 2007), is most advanced, and selected drugs have already entered clinical trials (Plummer, 2006; Plummer et al., 2008). Although mechanisms of PARP-1 inhibitor interactions with DNA damage repair processes are not entirely understood yet, pre-clinical evaluation has provided evidence for their use to potentate both chemotherapeutic agents and radiotherapy (Albert et al., 2007; Calabrese et al., 2004; Drew and Calvert, 2008), and also as single agents in BRCA related cancers (Jones and Plummer, 2008; Lord and Ashworth, 2008). Several studies have contributed to the appreciation of the role of PARP-1 in DNA repair processes (reviewed in (Helleday et al., 2005)). PARP-1 binds to DNA ssb and dsb and attracts ssb repair proteins. Notably, PARP-1 is involved in a backup dsb repair pathway but is not required for homologous recombination (HR). PARP-1 is important in maintaining genomic stability and increased sister chromatid exchange was observed in the absence of PARP-1 activity. This was explained by remaining unrepaired endogenous ssb leading to the collapse of replication forks which triggers recombination repair. In normal cells, the collapsed forks do not result in genetic instability as homologous recombination is an error-free repair pathway, but cells with defects in homologous recombination, e.g. BRCA mutant cells, are susceptible to PARP-1 inhibition (Farmer et al., 2005; Lord and Ashworth, 2008; McCabe et al., 2006), and PARP-1 inhibitors have been proposed as single or combination treatment in BRCA1/2 mutant tumours like breast and ovarian cancer (Drew and Calvert, 2008; Farmer et al., 2005). A most recent phase 1 trial with the PARP-1 inhibitor Olaparib (AZD2281) confirmed antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation (Fong et al., 2009).

Pharmacological inhibitors of the ATM protein kinase have also been proposed as radiosensitising agents since the inherited ataxia-telangiectasia (A-T) syndrome results in a profound hypersensitivity to ionising radiation (Cowell et al., 2005; Hickson et al., 2004; Hollick et al., 2007; Rainey et al., 2008; Sarkaria and Eshleman, 2001). KU-55933 is a novel, specific, and potent inhibitor of the ATM kinase which significantly sensitises cells to the cytotoxic effects of ionising radiation and to DNA dsb-inducing chemotherapeutic agents in pre-clinical evaluation (Hickson et al., 2004). The suitability of another non-toxic, specific and rapidly reversible ATM inhibitor CP466722 for the purpose of radiosensitisation has been reported most recently (Rainey et al., 2008).

DNA-PK was identified as another promising target for radiosensitisation. The DNA-PK inhibitor NU7441 has been evaluated in pre-clinical studies which demonstrate sufficient proof of principle through in vitro and in vivo chemosensitisation and radiosensitisation to justify further development of DNA-PK inhibitors for clinical use (Nutley et al., 2005; Veuger et al., 2003; Veuger et al., 2004; Willmore et al., 2004; Zhao et al., 2006).

The cell cycle checkpoint kinase Chk1 is another promising molecular target to enhance the cytotoxic effects of radiotherapy and chemotherapy in the treatment of certain cancers. Chk1 plays a major role in mediating S- and G2-arrest in response to DNA-damage. Inhibition of Chk1 enhances the cytotoxicity of DNA-damaging agents like ionising radiation through abrogation of these cell-cycle checkpoints. Convincing preclinical studies demonstrating radio- and chemosensitisation (Mack et al., 2004; Ree et al., 2004) have fuelled the development of a range of pharmacological Chk1 inhibitors (reviewed in (Tse et al., 2007)). UCN01 is a non-selective Chk1 inhibitor that has already been applied in clinical trials (Phase I/II) (Hotte et al., 2006; Welch et al., 2007), but pharmacokinetic data was unfavourable (Lara et al., 2005). Novel compounds have been developed since and entered first clinical trials, e.g. 17AAG (Phase I) and XL884 (Phase I) (Tse et al., 2007). CEP-3891 (Syljuasen et al., 2004), PF-00477736 (Blasina et al., 2008), isogranulatimide (Jiang et al., 2004) and AZD7762 (Zabludoff et al., 2008) are further examples of recently developed Chk1 inhibitors that undergo preclinical tests.

3. Understanding DNA damage and repair processes in bystander cells

In contrast to DNA damage induced by direct irradiation, bystander cell DNA damage is still poorly understood. The concept of signalling networks between irradiated cells and neighbouring non-irradiated cells resulting in the induction of DNA and chromosomal damage in non-irradiated cells, the so-called bystander effect, is relatively new and its potential role in cancer therapy has recently been discussed (Prise and O’Sullivan, 2009). Early events of the radiation induced bystander effect are rapid calcium fluxes and generation of reactive oxygen species in bystander cells (Azzam et al., 2002; Shao et al., 2006). Mitochondrial functions and mitochondria-dependent signalling seem to play a central role in bystander signalling (Chen et al., 2008; Tartier et al., 2007) and the relation between mitochondrial calcium signalling and reactive oxygen species production has previously been reviewed (Camello-Almaraz et al., 2006).

Several endpoints of studies on radiation-induced bystander effects are indicators of DNA and chromosomal damage in non-targeted cells. The induction of micronuclei (Azzam et al., 2002; Prise et al., 1998; Shao et al., 2005), γH2AX foci (Burdak-Rothkamm et al., 2007; Hu et al., 2006; Smilenov et al., 2006; Sokolov et al., 2005) and sister chromatid exchange (SCE) (Nagasawa et al., 2002; Nagasawa et al., 2005) in bystander cells clearly demonstrates the induction of DNA damage although the exact type of the initial damage is still a focus of investigation.

Bystander studies in double strand break repair (non-homologous end-joining) deficient cells (CHO xrs-5) showed marked induction of micronuclei (Kashino et al., 2004) and HPRT mutations (Nagasawa et al., 2003). Similar studies in p53 wild-type (TK6), p53 null (NH32), and p53 mutant (WTK1) lymphoblastoid cells using siRNA to knock down DNA PKcs confirmed a role of non-homologous end-joining in processing damage leading to increased mutation induction at the thymidine kinase locus in bystander cells. In contrast, knockdown of Rad54, a component of homologous recombination, had no impact on the mutation yield in bystander cells (Zhang et al., 2008). Homologous recombination is essential for the induction of sister chromatid exchanges in bystander cells, presumably through the contribution of Brca2 and the Rad51 paralogs to DNA damage repair processes induced in bystander cells which is thought to be via oxidative damage repair in S-phase cells (Nagasawa et al., 2008). However, homologous recombination is unable to repair the DNA damage induced in non-homologous end-joining -deficient bystander cells that leads to either sister chromatid exchanges or chromosomal aberrations (Nagasawa et al., 2005). From the study of repair deficient cell lines it is concluded that the repair phenotype of the cell receiving the bystander signal determines the overall response rather than that of the cell producing the bystander signal (Kashino et al., 2007).

Furthermore, RPA and apurinic/apyrimidinic endonuclease (APE, a key enzyme of the base excision repair pathway) showed enhanced expression in bystander cells which was attributed to a combination of DNA strand breaks and oxidized base lesions in the genomic DNA of bystander cells (Balajee et al., 2004).

Our recent studies into DNA damage signalling in cells receiving bystander signals have revealed a central role for the ATM- and Rad3-related (ATR) protein kinase. The induction of γH2AX foci in bystander cells depended on ATR function and bystander γH2AX foci predominantly occurred in S-phase cells (Burdak-Rothkamm et al., 2007). Similar results were obtained for bystander 53BP1 foci induction. Furthermore, ATM was activated in an ATR-dependent manner and was essential for the decrease in clonogenic survival of bystander cells. Either ATR or ATM deficiency led to the abrogation of bystander cell killing although the radiosensitivity of directly irradiated cells was increased. In contrast, DNA-PK function is not essential for bystander cell killing or bystander γH2AX foci induction. These observations provide a rationale for the differential modulation of targeted and non-targeted effects of radiation which could be exploited for the benefit of radiotherapy treatment regimes (Burdak-Rothkamm et al., 2008).

4. Differential modulation of targeted and non-targeted effects of ionising radiation by DNA repair inhibitors

As reviewed above, inhibitors of PARP-1, ATM, DNA-PK and Chk1 enhance the cytotoxic effect of ionising radiation. Previous in vitro studies focused on directly targeted cells where radiosensitisation was demonstrated, e.g. (Hickson et al., 2004; Mack et al., 2004; Noel et al., 2006; Veuger et al., 2003). Although targeted effects are probably most important for acute cytotoxicity of ionising radiation, a growing number of studies could demonstrate DNA and chromosome damage and reduced cell survival in non-irradiated bystander cells. Interestingly, the DNA damage in bystander cells seems to persist for a prolonged time (Burdak-Rothkamm et al., 2007) whereas DNA damage induced by direct irradiation is repaired completely within several hours depending on the radiation dose. Taking into account recent reports of the involvement of cytokines in the propagation of bystander effects (Shao et al., 2008; Shareef et al., 2007), it seems plausible that the radiation-induced bystander effect could trigger a systemic response affecting tissues away from the irradiated field, which was confirmed in recent studies (Koturbash et al., 2007; Koturbash et al., 2006). Therefore, bystander effects may be important for normal tissue reaction in radiotherapy treatment. Furthermore, DNA repair processes in bystander cells appear to be complex and may be triggered in S-phase when DNA damage interferes with replication fork progression (Burdak-Rothkamm et al., 2007; Nagasawa et al., 2008). The recent observations of the dependency of bystander γH2AX foci induction on ATR function but not on ATM or DNA-PK function (Burdak-Rothkamm et al., 2007) and dependency of bystander cell killing on ATR/ATM function (Burdak-Rothkamm et al., 2008) suggest potential targets for the modulation of bystander DNA damage. As it is desirable to protect bystander normal tissue in radiotherapy treatment, it is also important to further investigate the fate of cells rescued from bystander cell killing by ATR/ATM inhibition. The initial bystander DNA damage presumably is present in the rescued cells and may lead to genomic instability with an increased risk of (secondary) cancer (Morgan, 2003; Mothersill and Seymour, 2003). In contrast, the DNA-PK inhibitor NU7021 did not abrogate bystander cell killing (Burdak-Rothkamm et al., 2008) which is in keeping with previous observations of an increased bystander responses in non-homologous end-joining deficient xrs-5 CHO cells (Nagasawa and Little, 2002). Therefore, a DNA-PK inhibitor has the potential to radiosensitise both targeted and non-targeted cells.

No experimental data is available yet on the effect of PARP-1 or Chk1 inhibitors on bystander responses. The importance of PARP-1 in S-phase related DNA repair (Bryant and Helleday, 2006; Helleday et al., 2005) supports the hypothesis of a similar effect of PARP-1 inhibitors on bystander responses as ATR mutation, i.e. protection from cell death. Chk1 is a direct downstream target of ATR; its inhibition may therefore have a similar effect as ATR mutation on the bystander response. As both PARP-1 inhibitors and Chk1 inhibitors are advancing into clinical trials, it will be a key aim to establish their effect on bystander responses.

5. Conclusions

Our understanding of how radiation interacts with cells is evolving from one where direct radiation exposure of DNA within the cell nucleus drives response to one where cell to cell communication and in vivo, longer range bystander signalling also plays a role. Recent studies suggest that there are important differences between the DNA damage response in directly irradiated cells and non-targeted effects mediated via bystander signals. This may offer some novel routes for differential modulation of direct and bystander effects.

Table 1
Molecular inhibitors of DNA repair and cell cycle related proteins

Acknowledgements

The authors wish to acknowledge the support of Cancer Research UK [CUK] grant number C1513/A7047, the European Union NOTE project (FI6R 036465) and the US National Institutes of Health (5P01CA095227-02) for funding their work.

References

  • Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13:3033–3042. [PubMed]
  • Azzam EI, De Toledo SM, Spitz DR, Little JB. Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particle-irradiated normal human fibroblast cultures. Cancer Res. 2002;62:5436–5442. [PubMed]
  • Balajee AS, Ponnaiya B, Baskar R, Geard CR. Induction of replication protein a in bystander cells. Radiat Res. 2004;162:677–686. [PubMed]
  • Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O’Connor P, Anderes K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008;7:2394–2404. [PubMed]
  • Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res. 2006;34:1685–1691. [PMC free article] [PubMed]
  • Burdak-Rothkamm S, Rothkamm K, Prise KM. ATM acts downstream of ATR in the DNA damage response signaling of bystander cells. Cancer Res. 2008;68:7059–7065. [PMC free article] [PubMed]
  • Burdak-Rothkamm S, Short SC, Folkard M, Rothkamm K, Prise KM. ATR-dependent radiation-induced gammaH2AX foci in bystander primary human astrocytes and glioma cells. Oncogene. 2007;26:993–1002. [PubMed]
  • Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96:56–67. [PubMed]
  • Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Mitochondrial reactive oxygen species and Ca2+ signaling. Am J Physiol Cell Physiol. 2006;291:C1082–1088. [PubMed]
  • Chen S, Zhao Y, Han W, Zhao G, Zhu L, Wang J, Bao L, Jiang E, Xu A, Hei TK, Yu Z, Wu L. Mitochondria-dependent signalling pathway are involved in the early process of radiation-induced bystander effects. Br J Cancer. 2008 [PMC free article] [PubMed]
  • Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol. 2005;71:13–20. [PubMed]
  • Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res. 2004;10:881–889. [PubMed]
  • Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci. 2008;1138:136–145. [PubMed]
  • Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921. [PubMed]
  • Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134. [PubMed]
  • Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol. 1994;65:7–17. [PubMed]
  • Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle. 2005;4:1176–1178. [PubMed]
  • Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64:9152–9159. [PubMed]
  • Hollick JJ, Rigoreau LJ, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone MG, Menear KA, Martin NM, Matthews I, Newell DR, Ord R, Richardson CJ, Smith GC, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J Med Chem. 2007;50:1958–1972. [PubMed]
  • Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol. 2006;17:334–340. [PubMed]
  • Hu B, Wu L, Han W, Zhang L, Chen S, Xu A, Hei TK, Yu Z. The time and spatial effects of bystander response in mammalian cells induced by low dose radiation. Carcinogenesis. 2006;27:245–251. [PubMed]
  • Jiang X, Zhao B, Britton R, Lim LY, Leong D, Sanghera JS, Zhou BB, Piers E, Andersen RJ, Roberge M. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mol Cancer Ther. 2004;3:1221–1227. [PubMed]
  • Jones C, Plummer ER. PARP inhibitors and cancer therapy - early results and potential applications. Br J Radiol. 2008;81(1):S2–5. [PubMed]
  • Kashino G, Prise KM, Schettino G, Folkard M, Vojnovic B, Michael BD, Suzuki K, Kodama S, Watanabe M. Evidence for induction of DNA double strand breaks in the bystander response to targeted soft X-rays in CHO cells. Mutat Res. 2004;556:209–215. [PubMed]
  • Kashino G, Suzuki K, Matsuda N, Kodama S, Ono K, Watanabe M, Prise KM. Radiation induced bystander signals are independent of DNA damage and DNA repair capacity of the irradiated cells. Mutat Res. 2007;619:134–138. [PMC free article] [PubMed]
  • Koturbash I, Boyko A, Rodriguez-Juarez R, McDonald RJ, Tryndyak VP, Kovalchuk I, Pogribny IP, Kovalchuk O. Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo. Carcinogenesis. 2007;28:1831–1838. [PubMed]
  • Koturbash I, Rugo RE, Hendricks CA, Loree J, Thibault B, Kutanzi K, Pogribny I, Yanch JC, Engelward BP, Kovalchuk O. Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo. Oncogene. 2006;25:4267–4275. [PubMed]
  • Lara PN, Jr., Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005;11:4444–4450. [PubMed]
  • Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007;7:861–869. [PubMed]
  • Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008;8:363–369. [PubMed]
  • Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004;162:623–634. [PubMed]
  • McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115. [PubMed]
  • Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003;2:371–382. [PubMed]
  • Morgan WF. Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation? Oncogene. 2003;22:7094–7099. [PubMed]
  • Mothersill C, Seymour C. Radiation-induced bystander effects, carcinogenesis and models. Oncogene. 2003;22:7028–7033. [PubMed]
  • Nagasawa H, Cremesti A, Kolesnick R, Fuks Z, Little JB. Involvement of membrane signaling in the bystander effect in irradiated cells. Cancer Res. 2002;62:2531–2534. [PubMed]
  • Nagasawa H, Huo L, Little JB. Increased bystander mutagenic effect in DNA double-strand break repair-deficient mammalian cells. Int J Radiat Biol. 2003;79:35–41. [PubMed]
  • Nagasawa H, Little JB. Bystander effect for chromosomal aberrations induced in wild-type and repair deficient CHO cells by low fluences of alpha particles. Mutat Res. 2002;508:121–129. [PubMed]
  • Nagasawa H, Peng Y, Wilson PF, Lio YC, Chen DJ, Bedford JS, Little JB. Role of homologous recombination in the alpha-particle-induced bystander effect for sister chromatid exchanges and chromosomal aberrations. Radiat Res. 2005;164:141–147. [PubMed]
  • Nagasawa H, Wilson PF, Chen DJ, Thompson LH, Bedford JS, Little JB. Low doses of alpha particles do not induce sister chromatid exchanges in bystander Chinese hamster cells defective in homologous recombination. DNA Repair (Amst) 2008;7:515–522. [PubMed]
  • Noel G, Godon C, Fernet M, Giocanti N, Megnin-Chanet F, Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther. 2006;5:564–574. [PubMed]
  • Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer. 2005;93:1011–1018. [PMC free article] [PubMed]
  • Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol. 2006;6:364–368. [PubMed]
  • Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7917–7923. [PMC free article] [PubMed]
  • Prise KM, Belyakov OV, Folkard M, Michael BD. Studies of bystander effects in human fibroblasts using a charged particle microbeam. Int J Radiat Biol. 1998;74:793–798. [PubMed]
  • Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9:351–360. [PMC free article] [PubMed]
  • Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008;68:7466–7474. [PMC free article] [PubMed]
  • Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol. 2004;72:305–310. [PubMed]
  • Sarkaria JN, Eshleman JS. ATM as a target for novel radiosensitizers. Semin Radiat Oncol. 2001;11:316–327. [PubMed]
  • Shao C, Folkard M, Michael BD, Prise KM. Bystander signaling between glioma cells and fibroblasts targeted with counted particles. Int J Cancer. 2005;116:45–51. [PubMed]
  • Shao C, Folkard M, Prise KM. Role of TGF-beta1 and nitric oxide in the bystander response of irradiated glioma cells. Oncogene. 2008;27:434–440. [PMC free article] [PubMed]
  • Shao C, Lyng FM, Folkard M, Prise KM. Calcium fluxes modulate the radiation-induced bystander responses in targeted glioma and fibroblast cells. Radiat Res. 2006;166:479–487. [PubMed]
  • Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, Mohiuddin M, Rangnekar VM, Ahmed MM. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 2007;67:11811–11820. [PubMed]
  • Smilenov LB, Hall EJ, Bonner WM, Sedelnikova OA. A microbeam study of DNA double-strand breaks in bystander primary human fibroblasts. Radiat Prot Dosimetry. 2006;122:256–259. [PubMed]
  • Sokolov MV, Smilenov LB, Hall EJ, Panyutin IG, Bonner WM, Sedelnikova OA. Ionizing radiation induces DNA double-strand breaks in bystander primary human fibroblasts. Oncogene. 2005;24:7257–7265. [PubMed]
  • Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res. 2004;64:9035–9040. [PubMed]
  • Tartier L, Gilchrist S, Burdak-Rothkamm S, Folkard M, Prise KM. Cytoplasmic irradiation induces mitochondrial-dependent 53BP1 protein relocalization in irradiated and bystander cells. Cancer Res. 2007;67:5872–5879. [PMC free article] [PubMed]
  • Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6:945–956. [PubMed]
  • Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res. 2007;13:1955–1960. [PubMed]
  • Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003;63:6008–6015. [PubMed]
  • Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene. 2004;23:7322–7329. [PubMed]
  • Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S, Pond GR, Dancey JE, Oza AM. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol. 2007;106:305–310. [PubMed]
  • Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood. 2004;103:4659–4665. [PubMed]
  • Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7:2955–2966. [PubMed]
  • Zhang Y, Zhou J, Held KD, Redmond RW, Prise KM, Liber HL. Deficiencies of Double-Strand Break Repair Factors and Effects on Mutagenesis in Directly gamma-Irradiated and Medium-Mediated Bystander Human Lymphoblastoid Cells. Radiat Res. 2008;169:197–206. [PubMed]
  • Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006;66:5354–5362. [PubMed]